LBA2 Lorlatinib vs crizotinib in the first-line treatment of patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC): Results of the phase III CROWN study

Annals of Oncology ◽

10.1016/j.annonc.2020.08.2282 ◽

2020 ◽

Vol 31 ◽

pp. S1180-S1181 ◽

Author(s):

B. Solomon ◽

T.M. Bauer ◽

F. De Marinis ◽

E. Felip ◽

Y. Goto ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

Alk Positive ◽

First Line Treatment

Download Full-text

PCN152 - COST EFFECTIVENESS OF ALECTINIB IN THE FIRST LINE TREATMENT OF ADVANCED ALK-POSITIVE NON-SMALL CELL LUNG CANCER IN TURKEY

Value in Health ◽

10.1016/j.jval.2018.09.235 ◽

2018 ◽

Vol 21 ◽

pp. S40

Author(s):

E. Öksüz ◽

S. Malhan ◽

L. Yanik ◽

E. Koc ◽

E. Erdogan-Ciftci ◽

...

Keyword(s):

Lung Cancer ◽

Cost Effectiveness ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Alk Positive ◽

First Line Treatment

Download Full-text

Randomized phase III trial of amrubicin/cisplatin versus etoposide/cisplatin as first-line treatment for extensive small-cell lung cancer

10.1186/s12885-016-2301-6 ◽

2016 ◽

Vol 16 (1) ◽

Author(s):

Yan Sun ◽

Ying Cheng ◽

Xuezhi Hao ◽

Jie Wang ◽

Chengping Hu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

First-line treatment of advanced ALK-positive non-small-cell lung cancer

Lung Cancer Targets and Therapy ◽

10.2147/lctt.s63491 ◽

2015 ◽

pp. 71 ◽

Author(s):

Grace Dy ◽

Shipra Gandhi ◽

Hongbin Chen ◽

Yujie Zhao

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Line Treatment ◽

Small Cell Lung ◽

Alk Positive ◽

First Line Treatment

Download Full-text

Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 as first line treatment of advanced non-small cell lung cancer (NSCLC)

Journal of Clinical Oncology ◽

10.1200/jco.2008.26.15_suppl.8016 ◽

2008 ◽

Vol 26 (15_suppl) ◽

pp. 8016-8016 ◽

Author(s):

V. Hirsh ◽

M. Boyer ◽

R. Rosell ◽

R. J. Benner ◽

D. Readett ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

Phase Iii Trial ◽

First Line Treatment

Download Full-text

PD4-2-3: Global Lung Oncology Branch trial 3 (Glob 3): final results of a randomised multinational Phase III study of oral and i.v. vinorelbine (NVB) plus cisplatin (CDDP) versus docetaxel (DTX) plus CDDP as first-line treatment for advanced Non-Small Cell Lung Cancer (NSCLC)

Journal of Thoracic Oncology ◽

10.1097/01.jto.0000283381.78585.f2 ◽

2007 ◽

Vol 2 (8) ◽

pp. S451

Author(s):

Eng-Huat Tan ◽

Tomasz Grodzki ◽

Claus-Peter Schneider ◽

Peter Zatloukal ◽

Martin Reck ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Atezolizumab Plus Chemotherapy for First-Line Treatment of Non-Squamous Non-Small Cell Lung Cancer: Results From the Randomized Phase III IMpower132 Trial

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2020.11.025 ◽

2020 ◽

Author(s):

Makoto Nishio ◽

Fabrice Barlesi ◽

Howard West ◽

Simon Ball ◽

Rodolfo Bordoni ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text

Global Lung Oncology Branch trial 3 (GLOB3): final results of a randomised multinational phase III study alternating oral and i.v. vinorelbine plus cisplatin versus docetaxel plus cisplatin as first-line treatment of advanced non-small-cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdn774 ◽

2009 ◽

Vol 20 (7) ◽

pp. 1249-1256 ◽

Author(s):

E.H. Tan ◽

J. Rolski ◽

T. Grodzki ◽

C.P. Schneider ◽

U. Gatzemeier ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

The PARAMOUNT Trial: A Phase III Randomized Study of Maintenance Pemetrexed Versus Placebo Immediately Following Induction First-line Treatment with Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non-Small Cell Lung Cancer

Reviews on Recent Clinical Trials ◽

10.2174/15748871112079990040 ◽

2013 ◽

Vol 8 (1) ◽

pp. 23-28 ◽

Author(s):

Cesare Gridelli ◽

Paolo Maione ◽

Antonio Rossi

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Randomized Study ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

First Line Treatment

Download Full-text

P-452 Phase III study of docetaxel-cisplatin (DC) or docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) as first-line treatment of advanced non-small cell lung cancer (NSCLC): Analyses by gender

Lung Cancer ◽

10.1016/s0169-5002(05)80945-6 ◽

2005 ◽

Vol 49 ◽

pp. S235 ◽

Author(s):

C. Belani ◽

J. von Pawel ◽

A. Pluzanska ◽

V. Gorbounova ◽

E. Kaukel ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

Phase Iii Study ◽

First Line Treatment

Download Full-text

Apatinib plus gefitinib as first-line treatment in advanced EGFR-mutant non-small cell lung cancer: the phase III ACTIVE study (CTONG1706)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2021.05.006 ◽

2021 ◽

Author(s):

Hongyun Zhao ◽

Wenxiu Yao ◽

Xuhong Min ◽

Kangsheng Gu ◽

Guohua Yu ◽

...

Keyword(s):

Lung Cancer ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Phase Iii ◽

Line Treatment ◽

Small Cell Lung ◽

Egfr Mutant ◽

First Line Treatment

Download Full-text